Cost-effectiveness of osimertinib for EGFR-mutation-positive non-small-cell lung cancer after progression of first-line EGFR TKI therapy.

Bin Wu,Xiaohua Gu,Qiang Zhang

DOI: https://doi.org/10.1016/j.jtho.2017.10.012

IF: 20.121

2018-01-01

Journal of Thoracic Oncology

Abstract:To investigate the cost-effectiveness of osimertinib for the treatment of advanced non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) T790M mutation after the failure of first-line EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy.A mathematical model was established by combining a decision tree and the Markov approach to project the cost-effectiveness of osimertinib for the treatment of patients who harbor an EGFR T790M mutation compared to that of standard chemotherapy, who had disease progression after first-line EGFR-TKI therapy with or without metastases to the central nervous system. The clinical and outcome data were derived from randomized clinical trials and published reports. The health outcome data included the quality-adjusted life-years (QALYs). The cost data were estimated from the perspectives of the payer in the United States and the health care system in China. All costs and incremental cost-effectiveness ratios (ICER) were presented in 2017 US dollars. Sensitivity and scenario analyses with three different settings of T790M mutation testing were performed.Compared with chemotherapy, molecular testing in plasma and tissue followed by osimertinib treatment yielded an additional 0.434 and 0.379 QALYs in the entire United States population and the central nervous system (CNS) metastases population with an EGFR T790M mutation. For these populations, the incremental cost was US$100,258 and $89,865 per patient, respectively, and the ICERs were $231,007 and $237,109/QALY, respectively. For the entire Chinese population and the Chinese population with CNS metastases, the ICERs were $45,022 and 49,760/QALY, respectively. For those with a known T790M mutation, the ICERs of osimertinib over chemotherapy also exceeded the willingness-to-pay threshold. The most influential parameter was the price of osimertinib.Osimertinib treatment for T790M mutation NSCLC is unlikely to be cost-effective from the perspectives of United States and China. If the price of osimertinib could be decreased, the economic outcome might become favorable.